Kristina Burow is a partner with ARCH Venture Partners, joining the firm in 2002. Her investment focus includes biotechnology, pharmaceuticals, alternative energy, and chemicals. Ms. Burow is a co-founder and director of Sapphire Energy and a director of Lycera, Receptos, and Limerick BioPharmaceuticals. She has participated in the funding and development of several other portfolio companies including Ensemble Discovery, Achaogen, Kythera Biopharmaceuticals, Ikaria, Accelerator Corporation and Quanterix.
Ms. Burow joined ARCH from the Novartis BioVenture Fund in San Diego where she was involved in numerous investments in the life science sector. Previously, as an early employee at the Genomics Institute of the Novartis Research Foundation (GNF), she directed Chemistry Operations and was active in Business Development.
Ms. Burow holds an M.B.A. from The University of Chicago, an M.A. in Chemistry from Columbia University, and a B.S. in Chemistry from the University of California, Berkeley.